(Health Korea News / Changyong Lee) ‘Pharmaceutical 24 Hours’ is a corner that shows brief news related to pharmaceutical and biotechnology at a glance that is easy to miss. It may seem like trivial news, but it could be valuable information to someone, so we summarize the facts and present them in an easy-to-understand manner.
◆ Celltrion conducts wild bird protection activities as part of strengthening ESG management activities
Celltrion announced on the 11th that as part of its biodiversity conservation activities, it had jointly carried out ESG activities to protect wild birds with the Incheon Green Alliance, a local civic group.
Many local volunteers, including Celltrion executives and employees, participated in this event and installed bird collision prevention stickers that wild birds can recognize on some sections of the transparent soundproof wall installed on the road near Yongyu Station in Yeongjong Island, Incheon.
According to the Ministry of Environment, it is estimated that in Korea, about 8 million wild birds, including endangered species such as hawks and eagle owls, are injured or die every year when they collide with artificial structures such as transparent soundproof walls, buildings, and agricultural waterways.
Celltrion believes that this activity will help prevent the death of endangered wild birds caused by transparent soundproof walls and ensure safe movement rights. In fact, it is known that the collision reduction effect after attaching bird collision prevention stickers reaches more than 90%.
◆ Takeda Korea Pharmaceutical’s Alunbrick® successfully held the 2024 Korean Lung Cancer Society Satellite Symposium
Takeda Pharmaceutical Korea announced the clinical trial of Alunbrig® (ingredient name: brigatinib) as a first-line treatment for ALK-positive non-small cell lung cancer at the 2024 Korean Lung Cancer Association International Conference (KALC-IC 2024) held on the 7th and 8th. A Satellite Symposium was successfully held to emphasize its significance.
This satellite symposium was held under the theme ‘Translating clinical trial results into real-world impact: Brigatinib case studies’, and was conducted by Lee Ki-hyung, Department of Hematology and Oncology, Chungbuk National University Hospital. The professor participated as moderator, and Professor Ki-Peum Lee of the Department of Oncology at the Lung Cancer Center of Sinchon Severance Hospital and Yonsei Cancer Hospital participated as a speaker.
Among the data introduced by Professor Kippeum Lee, there were Real-World Data (RWD), which analyzed the primary treatment results of ALK-positive non-small cell lung cancer patients in Korea, and the results of the phase 2 clinical trial J-ALTA study conducted in Japan. included. In particular, the domestic real-world data is the result of a study that analyzed the treatment response of 32 patients who took Alunbrig® and 176 patients who took alectinib as primary treatment.
As a result of the analysis, the objective response rate (ORR) was 93.8% for ALUNBRIG® and 92.5% for alectinib (p=0.53; 95% CI, 0.28–6.07), and the intracranial objective response rate (iORR) was Alunbrig® was found to be 100% (10/10), and Alectinib was 92.7% (38/41). The progression-free survival (PFS rate) at 12 months was similar in both the Alunbrig® treatment group and the alectinib treatment group (84.4% vs. 84.1%, p-value: 0.97), and overall, Alunbrig® was It has shown clinical value similar to alectinib.
◆ Daewon Pharmaceutical holds a kickoff event for a new start with ‘Shinbaro’
Daewon Pharmaceutical announced on the 11th that it held the ‘Shinbaro 2025 Kick-Off Meeting’ at Sebitseom Floating Island located in Seocho-gu, Seoul to commemorate the new start of ‘Shinbaro’, a natural medicine for treating osteoarthritis, and pledge its success.
This event, attended by a total of about 500 people, including CEO Baek In-hwan and executives and employees from the sales division and related departments, was organized to commemorate the recent complete transfer of ownership from GC Green Cross to Shinba and to strengthen resolutions for a new start.
The event began with executives and employees gathering at a banquet hall to hold various events and have lunch together, followed by a presentation on the background and vision for introducing Shinbaro, an awards ceremony for excellent salespeople, and Q&A.
Shinbaro is Korea’s fourth natural new drug and is used for anti-inflammatory, pain-relieving, and osteoarthritis treatments. It is composed of 6 plant extracts, including apricot root, percussion root, and percussion root, and is characterized by a low incidence of adverse gastrointestinal reactions even during long-term administration.
◆ Medytox holds academic program ‘M.LAB Medical Training’… After expanding exchanges
Global biopharmaceutical company Medytox held an academic program ‘M.LAB (Medytox Leader Advance Beginner) Medical Training’ for domestic medical experts at the Beauty Lounge Clinic Cheonan branch on the 9th.
‘M.LAB Medical Training’, which has been running regularly since July of this year, is one of the programs of Medytox’s representative academic program ‘M.LAB’, and consists of Beginner, Advanced, and Leader courses and includes customized lectures and live demonstrations on botulinum toxin and fillers. etc. are provided.
About 20 medical experts attended the ‘M.LAB Medical Training’ held on this day. Beauty Lounge Clinic director Kim Se-jin gave an in-depth lecture on fillers using hyaluronic acid fillers ‘Neuramis Light Lidocaine’, ‘Neuramis Lidocaine’, and ‘Neuramis Deep Lidocaine’. A live demonstration was conducted along with the theory of filler treatment to help understand the safe and effective treatment method.
Meanwhile, ‘M.LAB’, an academic education program hosted by Medytox, invites experts in the cosmetic surgery field as speakers and provides quality medical services, including ‘medical training’ to increase understanding of toxins and fillers for domestic medical personnel. It consists of ‘Medical Consulting’, which transfers consultation know-how for medical treatment, and ‘Product Specialist’, which fosters internal experts on Medytox products.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
